点鼻スプレーの世界市場（2025年～2033年）

世界の点鼻スプレーの市場規模は、2024年に241億6,000万米ドルに達し、2033年には405億9,000万米ドルに達すると予測され、予測期間2025年～2033年のCAGRは6.1%で成長する見通しです。

点鼻スプレーは、鼻孔に微細な霧として投与され、鼻粘膜からの直接吸収を可能にする薬剤の一形態です。このタイプの送達は、アレルギーの緩和、鼻づまりの解消、さらには予防接種など、幅広い治療に特に有用です。液状の薬剤を特殊な技術で微粒子化することで、鼻腔内に容易に吸入させ、迅速かつ効率的に治療効果を発揮させることができます。

世界の点鼻スプレー市場は、製品リリースや承認の増加など、多くの要因によって急速に拡大しています。この動向の主な要因は、呼吸器疾患やアレルギーの有病率が上昇し、効果的な代替治療に対する需要が高まっていることです。点鼻スプレーは、その使用の利便性、迅速な作用開始、鼻粘膜に直接薬剤を投与する能力により、人気が高まっています。

市場力学：

促進要因と抑制要因

点鼻スプレーの上市と承認の増加

点鼻スプレーの上市と承認の増加は、世界の点鼻スプレー市場の成長における重要な要因になると予想されます。この拡大の主な要因の一つは、アレルギー性鼻炎、副鼻腔炎、その他の呼吸器疾患などの呼吸器系疾患の有病率の上昇です。これらの病気に関する知識が深まるにつれ、より多くの人々が効果的な治療法を求めるようになり、その結果、点鼻スプレー医薬品の開発と承認が増加しています。例えば、2024年8月、米国食品医薬品局は、ネフィ（エピネフリン点鼻スプレー）を、体重30キロ（66ポンド）以上の成人および小児患者における、生命を脅かすアナフィラキシーを含むアレルギー反応（タイプI）の緊急治療薬として承認しました。これらのスプレーは、鼻腔に直接薬剤を送達し、鼻づまりやアレルギーなどの問題を即座に緩和します。

さらに、2024年10月、エアロポンプとレシカは、ユニークなウルトラソフト鼻腔用ポンプスプレーの発売で協力しました。ウルトラソフト鼻腔用ポンプスプレーは、鼻腔から中枢神経系への非侵襲的ドラッグデリバリーを可能にし、鼻から脳への治療に理想的なものとなりました。さらに、規制当局によるジェネリック医薬品の認可も進んでおり、消費者にとってより利用しやすいものとなっています。この動向は、満たされていないヘルスケアニーズに対応するだけでなく、費用を削減し、研究開発に取り組んで独自の製剤を生み出し、特定の患者のニーズに応える鼻腔吸入器を発売することで、需要を向上させ、この分野のさらなる成長を支えています。

点鼻スプレー製品に関連する副作用

点鼻スプレー製品に関連する副作用などの要因は、世界の点鼻スプレー市場を妨げると予想されます。点鼻スプレーにはいくつかの副作用があります。例えば、ステロイドの点鼻スプレーを使用した後、鼻の刺すような感じや灼熱感、鼻のカサカサ感や乾燥感、喉の乾燥やかゆみ、口の中の悪味、鼻のかゆみ、赤み、腫れ、鼻からの出血などの副作用が観察されています。まれなことですが、重大な副作用として、視力障害や目のレンズが曇るなどの視力の変化、呼吸の問題が起こることがあります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
  • 点鼻スプレーの発売と承認の増加
  • 抑制要因
  • 点鼻スプレー製品に関連する副作用
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• 償還分析
• 特許分析
• SWOT分析
• DMIの見解

第6章 製品別

• 鼻づまり緩和点鼻スプレー
• 生理食塩水点鼻スプレー
• ステロイド点鼻スプレー
• その他

第7章 デザインタイプ別

• ポンプボトル
• 加圧キャニスター

第8章 治療薬別

• 抗ヒスタミン薬
• 鎮静鎮痛剤
• コルチコステロイド
• 併用薬
• その他

第9章 用途別

• 鼻づまり
• アレルギー性および非アレルギー性（通年性）鼻炎
• 副鼻腔炎
• 片頭痛
• その他

第10章 エンドユーザー別

• 病院
• 在宅ケア
• その他

第11章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• 中東・アフリカ

第12章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第13章 企業プロファイル

• Novartis AG
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Pfizer Inc.
• GSK Plc
• Sanofi
• Teva Pharmaceutical Industries Ltd.
• Novo Nordisk A/S
• Viatris Inc.
• Bayer
• Cipla
• AbbVie Inc.

第14章 付録

The Global Nasal Spray Market reached US$ 24.16 billion in 2024 and is expected to reach US$ 40.59 billion by 2033, growing at a CAGR of 6.1% during the forecast period 2025-2033.

A nasal spray is a form of medication that is administered as a fine mist into the nostrils, allowing for direct absorption via the nasal mucosa. This type of delivery is especially useful for a wide range of treatments, including allergy relief, decongestion, and even immunization. The liquid drug is atomized with a specialized technology, allowing it to be easily breathed into the nasal passages and exhibit its therapeutic effects swiftly and efficiently.

The global nasal spray market is expanding rapidly, owing to a number of factors such as increased product releases and approvals. This trend is mostly driven by the rising prevalence of respiratory diseases and allergies, which has increased demand for effective treatment alternatives. Nasal sprays are becoming more popular due to their convenience of use, quick start of action, and ability to administer medication directly to the nasal mucosa.

Market Dynamics: Drivers & Restraints

Increasing launches and approvals of nasal spray

The increasing launches and approvals of nasal spray are expected to be a significant factor in the growth of the global nasal spray market. One of the key drivers of this expansion is the rising prevalence of respiratory diseases such as allergic rhinitis, sinusitis, and other respiratory ailments. As knowledge of these illnesses grows, more people are looking for effective treatments, resulting in an increase in the development and approval of nasal spray medicines. For instance, in August 2024, the United States Food and Drug Administration approved neffy (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including life-threatening anaphylaxis, in adult and pediatric patients weighing at least 30 kilograms (66 pounds). These sprays deliver drugs straight to the nasal passages, offering immediate relief from problems such as congestion and allergies.

Moreover, in October 2024, Aero Pump and Resyca collaborated on the launch of the unique Ultra Soft Nasal Pump Spray. The Ultra Soft Nasal Pump Spray has enabled non-invasive drug delivery to the central nervous system via the nasal canal, making it ideal for nose-to-brain therapy. Additionally, regulatory agencies are progressively authorizing generic nasal spray products, making them more accessible to consumers. This trend not only addresses unmet healthcare needs but also reduces expenses, working on research and development to generate unique formulations and launch nasal inhalers that cater to specific patient needs, thus improving their demand and supporting further growth within the sector.

Side effects associated with nasal spray products

Factors such as the side effects associated with nasal spray products are expected to hamper the global nasal spray market. Several side effects are shown by the nasal sprays. For instance, after using steroid nasal spray a stinging or burning feeling in the nose, crustiness or dryness in the nose, a dry and itchy throat, a bad taste in the mouth, itching, redness, or swelling in the nose, and bleeding from the nose are possible side effects have been observed. Although they are uncommon, serious side effects can include changes in vision, such as impaired vision an eye lens that is foggy, or breathing issues.

Segment Analysis

The Global Nasal Spray Market is segmented based on Product, Design Type, Therapeutic Drugs, Application, End-User, And Region.

The steroid nasal spray segment is expected to dominate the global nasal spray market share

The steroid nasal spray segment is anticipated to dominate the global nasal spray market owing to its effectiveness in treating various chronic respiratory disorders, technological advancements, recent launches, and approvals. Steroid nasal sprays are widely used by consumers and healthcare providers due to their effectiveness in treating a variety of diseases, including allergic rhinitis, sinusitis, and nasal polyps. These sprays work by delivering corticosteroids directly into the nasal passages, thereby reducing inflammation, mucus production, and congestion, which are common symptoms associated with these conditions.

The introduction of aqueous formulations is a crucial technological achievement that has contributed to the proliferation of steroid nasal sprays. These formulations improve corticosteroid delivery directly to the nasal mucosa, increasing medication absorption while reducing systemic side effects. The aqueous-based sprays are intended to provide a more comfortable application experience for users, which has proved critical in increasing patient adherence to treatment regimens. There are recent launches of such steroid nasal sprays that are manufactured using advanced technology.

For instance, in May 2023, Bausch Health Companies Inc. launched and made its new prescription nasal spray, RYALTRIS (olopatadine hydrochloride and mometasone furoate nasal spray), available throughout Canada. Health Canada has approved RYALTRIS for the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and related ocular symptoms in adults, adolescents, and children aged 6 and up. The domination of steroid nasal sprays in the global nasal spray market can be attributed to technological developments in formulation and delivery systems, as well as greater accessibility through generics. These reasons all contribute to the continued expansion and increasing acceptance of steroid nasal sprays as a therapeutic option for a variety of nasal disorders making it the most dominating segment.

Geographical Analysis

North America is expected to hold a significant position in the global nasal spray market share

North America will likely account for a significant share of the global nasal spray market, owing to its advanced healthcare infrastructure and substantial healthcare expenditures, technological advancements, and recent launches and approvals. One of the most significant technological developments in the North American nasal spray market has been the development of novel medication formulations. Manufacturers are working to provide more effective and patient-friendly solutions, such as aqueous formulations that improve drug absorption while minimizing potential side effects.

For instance, in February 2024, Lupin Limited (Lupin) announced the launch of Cyanocobalamin Nasal Spray in the United States, following approval from the United States Food and Drug Administration. Cyanocobalamin Nasal Spray, 500 mcg/spray (One Spray per Device) is a generic version of Nascobal Nasal Spray, 500 mcg/spray by Par Pharmaceutical, Inc. These formulations enable more effective delivery of active substances directly to the nasal mucosa, which is especially useful for treating allergic rhinitis and sinusitis. The transition to more effective formulations has resulted in improved patient compliance and satisfaction.

Furthermore, advances in distribution systems have played an important part in the market's expansion. The development of metered-dose inhalers and pump spray technologies has increased dosing precision, ensuring that patients get the right quantity of medication with each use. The major players in this region are researching and developing various nasal sprays and the latest advanced technology is used in the manufacture, making them user-friendly they are manufactured in large quantities to meet the increasing demand for nasal inhalers across the region. All these factors together contribute to the largest market share in the region of North America.

Asia Pacific is growing at the fastest pace in the global nasal spray market

The Asia Pacific region is emerging as the fastest-growing market for nasal spray, owing to demographic shifts, increasing healthcare expenditures, technological advancements, rising number of chronic respiratory disorders. One of the primary reasons for this trend is the rising incidence of allergies and respiratory diseases in densely populated areas. Urbanization, environmental pollution, and lifestyle changes have all contributed to a rise in allergic conditions in the Asia Pacific region.

For instance, according to the National Institute of Health, Allergic conditions, such as allergic rhinitis (AR) and asthma, appear to be on the rise in India over the last several decades. AR affects approximately 22% of adolescents in India. The total prevalence of asthma in India is 34.3 million, accounting for 13.09% of the global burden. Asthma caused 27.9% of disability-adjusted life years (DALYs) in the Indian population. Nasal sprays, particularly those containing corticosteroids or antihistamines, are popular due to their quick action and ease of application, making them an ideal alternative for treating symptoms associated with these medical conditions. The rising number of chronic respiratory disorders in this region increased the need and demand for nasal sprays which play a vital role in disease control and management and made the Asia Pacific region, the fastest-growing region.

Competitive Landscape

The major global players in the global nasal spray market include Novartis AG, Pfizer Inc., GSK Plc, Sanofi, Teva Pharmaceutical Industries Ltd., Novo Nordisk A/S, Viatris Inc., Bayer, Cipla, AbbVie Inc. among others.

Emerging Players

Biodeal Pharmaceuticals, Maya Biotech, and Nutra Respiro among others

Key Developments

• In August 2024, The United States Food and Drug Administration approved ARS Pharmaceuticals' (SPRY.O) nasal spray as the first needle-free emergency therapy for potentially fatal allergic reactions. The spray, known as Neffy, is being marketed as an alternative to the EpiPen and other autoinjectors containing epinephrine, a life-saving medicine used by those at risk of anaphylaxis and other allergic responses.
• In April 2024, Firebrick Pharma launched their nasal spray product, Nasodine Nasal Spray, in the United States, making it the first in the world to be commercially available. Nasodine contains PVP-iodine, a broad-spectrum antiseptic best recognized for its extensive use in throat gargles under the brand name Betadine. Nasodine, a nasal spray, contains the same substance.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global nasal spray market report delivers a detailed analysis with 70+ key tables, more than 60 visually impactful figures, and 200 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product
• 3.2. Snippet by Design Type
• 3.3. Snippet by Therapeutic Drugs
• 3.4. Snippet by Application
• 3.5. Snippet by End-User
• 3.6. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
  • 4.1.2. Increasing Launches and Approvals of Nasal Spray
  • 4.1.3. Restraints
  • 4.1.4. Side Effects Associated with Nasal Spray Products
  • 4.1.5. Opportunity
  • 4.1.6. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Reimbursement Analysis
• 5.6. Patent Analysis
• 5.7. SWOT Analysis
• 5.8. DMI Opinion

6. By Product

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 6.1.2. Market Attractiveness Index, By Product
• 6.2. Decongestion Nasal Spray*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Saline Nasal Spray
• 6.4. Steroid Nasal Spray
• 6.5. Others

7. By Design Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design Type
  • 7.1.2. Market Attractiveness Index, By Design Type
• 7.2. Pump Bottles*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Pressurized Canisters

8. By Therapeutic Drugs

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Drugs
  • 8.1.2. Market Attractiveness Index, By Therapeutic Drugs
• 8.2. Antihistamines*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Sedative-Analgesics
• 8.4. Corticosteroids
• 8.5. Combination Drugs
• 8.6. Others

9. By Application

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.1.2. Market Attractiveness Index, By Application
• 9.2. Nasal Congestion*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Allergic and Non-Allergic (perennial) Rhinitis
• 9.4. Sinusitis
• 9.5. Migraine
• 9.6. Others

10. By End User

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.1.2. Market Attractiveness Index, By End User
• 10.2. Hospitals*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Homecare
• 10.4. Others

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design Type
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Drugs
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.8.1. U.S.
    • 11.2.8.2. Canada
    • 11.2.8.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design Type
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Drugs
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.8.1. Germany
    • 11.3.8.2. U.K.
    • 11.3.8.3. France
    • 11.3.8.4. Spain
    • 11.3.8.5. Italy
    • 11.3.8.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design Type
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Drugs
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.8.1. Brazil
    • 11.4.8.2. Argentina
    • 11.4.8.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design Type
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Drugs
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.8.1. China
    • 11.5.8.2. India
    • 11.5.8.3. Japan
    • 11.5.8.4. South Korea
    • 11.5.8.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design Type
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Drugs
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Novartis AG*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Pfizer Inc.
• 13.3. GSK Plc
• 13.4. Sanofi
• 13.5. Teva Pharmaceutical Industries Ltd.
• 13.6. Novo Nordisk A/S
• 13.7. Viatris Inc.
• 13.8. Bayer
• 13.9. Cipla
• 13.10. AbbVie Inc.

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us